Quoin Pharmaceuticals Financial Results
Quoin Pharmaceuticals reported third quarter 2026 financial results and provided a corporate update, including positive interim Phase 2/3 data for QRX003 in Netherton Syndrome. The company also highlighted a private placement financing of up to $50.0 million to fund the completion of QRX003 development. Topline data for the Netherton Syndrome study is expected in Q2 2027.
“The third quarter substantially strengthened Quoin’s clinical, regulatory and financial foundation for long-term growth. Interim clinical results from our Phase 2/3 study of QRX003 in Netherton Syndrome demonstrated statistical significance for the primary and key secondary endpoints, representing what we believe is the first ever overall positive data set published for this disease.”
Dr. Michael Myers, Chief Executive Officer and Co-Founder
“Our priorities for the coming months are very clear. We expect to complete recruitment in our Netherton Syndrome study by year end and report topline data in the second quarter of 2027.”
Dr. Michael Myers, Chief Executive Officer and Co-Founder